IBIO, INC. Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest
IBIO, INC. (IBIO) reported Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity · last filed 2023-09-27
- IBIO, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2023-03-31 was $0.00.
- IBIO, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2022-12-31 was $0.00.
- IBIO, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2022-09-30 was $0.00.
- IBIO, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for the quarter ending 2022-06-30 was $0.00.
- IBIO, INC. income (loss) from continuing operations, net of tax, attributable to noncontrolling interest for fiscal 2022 was -$1.00K.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2023-05-19 | $0.00 derived: sum of 3 quarters · filed 2023-05-19 | $0.00 derived: sum of 4 quarters · filed 2023-09-27 |
| 2022-12-31 | $0.00 10-Q/A · filed 2023-05-19 | $0.00 derived: sum of 2 quarters · filed 2023-05-19 | $0.00 derived: sum of 3 quarters · filed 2023-09-27 | $0.00 derived: sum of 4 quarters · filed 2023-09-27 |
| 2022-09-30 | $0.00 10-Q · filed 2022-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-09-27 | $0.00 derived: sum of 3 quarters · filed 2023-09-27 | $0.00 derived: sum of 4 quarters · filed 2023-09-27 |
| 2022-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-27 | $0.00 derived: sum of 2 quarters · filed 2023-09-27 | $0.00 derived: sum of 3 quarters · filed 2023-09-27 | -$1.00K 10-K · filed 2023-09-27 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 | $0.00 derived: sum of 2 quarters · filed 2023-05-19 | -$1.00K 10-Q · filed 2023-05-15 | |
| 2021-12-31 | $0.00 10-Q/A · filed 2023-05-19 | -$1.00K 10-Q/A · filed 2023-05-19 | ||
| 2021-09-30 | -$1.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |